BCTX News and Press, BriaCell Therapeutics Corp. From 08/25/23

August 31, 2023 is the expected effective date for the distribution contemplated by the Arrangement. PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-sta...

Shareholders overwhelmingly approved the spinout of BriaPro Therapeutics (Spinco) which includes specific pipeline assets including Bria-TILsRx and and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer Share reorganization expected to take place...

NCI award (non-dilutive grant) further validates novel personalized off-the-shelf immunotherapy approach; and may facilitate future non-dilutive funding opportunities PHILADELPHIA and VANCOUVER, British Columbia, Aug. 16, 2023 (GLOBE NEWSWIRE) --  BriaCell Therapeutics Corp. (Nasda...

2023-08-07 16:00:36 ET Moleculin ( NASDAQ: MBRX ) said that it has retained analytics firm Shareholder Intelligence Services, or ShareIntel, to investigate potential naked short selling of its shares. The company said that information provided by ShareIntel will help it identify...

A significant medical breakthrough is needed in the fight against metastatic breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of invasive breast cancer. However, there’s hope for treatment, with companies like BriaCe...

PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and improve patients’ lives,...

2023-05-25 09:34:36 ET A clinical-stage biotechnology company specialising in targeted immunotherapies for cancer, BriaCell Therapeutics ( NASDAQ: BCTX ) enters into an agreement with BriaPro Therapeutics, a wholly-owned subsidiary  pursuant to which certain pre-clinical ...

Special Shareholder Meeting to be Held in July 2023 PHILADELPHIA and VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotech...

PHILADELPHIA and VANCOUVER, British Columbia, May 19, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is ple...

2023-05-15 09:19:47 ET BriaCell ( NASDAQ: BCTX ) announced that Prevail Partners had agreed to purchase 463K of its common shares at $8.63 per share, resulting in $4M in gross proceeds, and revealed that Prevail InfoWorks had also been chosen as the CRO for their upcoming pivo...